Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S.

Johnson & Johnson (NYSE: JNJ) announced on Thursday that it has reached a significant agreement with the Donald Trump administration to reduce drug prices for American consumers in exchange for an exemption from U.S. trade tariffs. The deal positions the pharmaceutical giant among a growing list of drugmakers cooperating with the White House on healthcare affordability and domestic investment.

In an official press release, Johnson & Johnson stated that the joint agreement fulfills requests made by President Trump to the pharmaceutical industry. As part of the arrangement, the company’s pharmaceutical products will be exempt from tariffs that were previously imposed on imported medicines. These tariffs, which reached as high as 100%, were introduced to pressure drugmakers into lowering prices and expanding manufacturing operations within the United States.

Johnson & Johnson confirmed it is collaborating closely with the Trump administration on multiple initiatives designed to improve access to healthcare and prescription medications for American patients. One of the key measures includes participation in the TrumpRx.gov program, a federal initiative aimed at increasing price transparency and offering more comparable pricing on treatments across the U.S. market. The company also pledged to align its pricing strategies more closely with domestic affordability goals.

In addition to pricing reforms, Johnson & Johnson announced plans to expand its U.S. manufacturing footprint. The company revealed it will build two new production facilities in Pennsylvania and North Carolina as part of a broader $55 billion investment commitment in the United States. Johnson & Johnson added that further investment announcements are expected later this year, reinforcing its long-term strategy to strengthen domestic supply chains and job creation.

The announcement comes just weeks after the Trump administration disclosed similar agreements with nine major pharmaceutical companies to cut medicine prices for American consumers. Since taking office last year, President Trump has repeatedly emphasized lowering drug costs as a central policy goal, frequently linking tariff exemptions to commitments for U.S.-based manufacturing and consumer price reductions.

By combining lower drug prices, expanded U.S. investments, and tariff relief, the Johnson & Johnson agreement reflects the administration’s broader approach to reshaping the pharmaceutical industry while addressing healthcare affordability concerns.